Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Excretion Clear all
Completed Phase 1 Interventional

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

NCT00730145
View directory record Official record
Conditions
Renal Dialysis, Pharmacokinetics
Interventions
PD-0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 26, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

NCT00729365
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Gainesville, Florida • Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

NCT00296400
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
23
States / cities
Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Peripheral Dopamine in Postural Tachycardia Syndrome

NCT00685919
View directory record Official record
Conditions
Postural Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Carbidopa, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 26, 2026, 5:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

NCT00721422
View directory record Official record
Conditions
Renal Insufficiency, Pharmacokinetics
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 26, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Study of Renal Denervation in Patients With Heart Failure

NCT01954160
View directory record Official record
Conditions
Heart Failure
Interventions
Symplicity Renal Denervation
Device
Lead sponsor
Adrian Hernandez
Other
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

NCT01581996
View directory record Official record
Conditions
Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis
Interventions
lanthanum carbonate
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Early Phase 1 Interventional

Study of Sodium Bicarbonate in Kidney Transplant Recipients

NCT01225796
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Sodium bicarbonate
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 26, 2026, 5:13 AM EDT
Withdrawn Phase 2Phase 3 Interventional

The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium

NCT00948740
View directory record Official record
Conditions
Vitamin D Deficiency, Nephrolithiasis
Interventions
vitamin D (ergocalciferol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02289755
View directory record Official record
Conditions
Hyperoxaluria, Nephrolithiasis
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Lake Success, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 26, 2026, 5:13 AM EDT
Not listed Phase 2 Interventional

Bucillamine Phase 2 Trial in Patients With Cystinuria

NCT02942420
View directory record Official record
Conditions
Cystinuria
Interventions
Bucillamine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Basis for Variation in the Renal Elimination of Metformin

NCT00187720
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acid-Base Compensation in Chronic Kidney Disease

NCT02427594
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Controlled diet
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion

NCT03752684
View directory record Official record
Conditions
Calcium Oxalate Urolithiasis
Interventions
Moderately high oxalate/low calcium diet non-colonized, Oxalobacter formigenes, Moderately high oxalate/low calcium diet colonized
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 26, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077
View directory record Official record
Conditions
Osteoporosis
Interventions
rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 26, 2026, 5:13 AM EDT